Gefitinib Tablet, Coated
NDC Package 67184-0531-1
Package Information
Gefitinib tablets is are indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test [see Clinical Studies (14)].Limitation of Use: Safety and efficacy of gefitinib tablets have not been established in patients with metastatic NSCLC whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations [see Clinical Studies (14)]. This formulation utilizes a tablet, coated delivery system. Marketed by Qilu Pharmaceutical Co., Ltd., this product is identified by NDC 67184-0531 and is authorized under FDA application ANDA211591.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 67184 - Qilu Pharmaceutical Co., Ltd.
- 67184-0531 - Gefitinib
- 67184-0531-1 - 30 TABLET, COATED in 1 BOTTLE
- 67184-0531 - Gefitinib
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (67184-0531). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 67184-0531-1 identifies a specific commercial package of 30 tablet, coated in 1 bottle of Gefitinib, a human prescription drug labeled by Qilu Pharmaceutical Co., Ltd.. This tablet, coated is formulated for oral use and contains gefitinib as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Qilu Pharmaceutical Co., Ltd. on February 13, 2023. The current certification is valid through December 31, 2027.
How is this Qilu Pharmaceutical Co., Ltd. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 67184053101. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.